CA3140231C - Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee - Google Patents

Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee Download PDF

Info

Publication number
CA3140231C
CA3140231C CA3140231A CA3140231A CA3140231C CA 3140231 C CA3140231 C CA 3140231C CA 3140231 A CA3140231 A CA 3140231A CA 3140231 A CA3140231 A CA 3140231A CA 3140231 C CA3140231 C CA 3140231C
Authority
CA
Canada
Prior art keywords
compound
pain
formula
substituted
another preferred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3140231A
Other languages
English (en)
Other versions
CA3140231A1 (fr
Inventor
Youxin WANG
Lingling Zhang
Qiang Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Leado Pharmatech Co Ltd
Original Assignee
Shanghai Leado Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2019/100846 external-priority patent/WO2020035040A1/fr
Application filed by Shanghai Leado Pharmatech Co Ltd filed Critical Shanghai Leado Pharmatech Co Ltd
Priority claimed from PCT/CN2020/090354 external-priority patent/WO2020228789A1/fr
Publication of CA3140231A1 publication Critical patent/CA3140231A1/fr
Application granted granted Critical
Publication of CA3140231C publication Critical patent/CA3140231C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, une forme cristalline et une utilisation associée. Plus particulièrement, la présente invention concerne un composé, ou un sel pharmaceutiquement acceptable ou un promédicament de celui-ci, le composé ayant une structure de formule I. Le composé, ou un sel pharmaceutiquement acceptable ou un promédicament de celui-ci selon la présente invention a une excellente fonction d'inhibition pour une protéine de canal à potentiel de récepteur transitoire (TPR), et a une bonne fonction de traitement pour des maladies associées au TPR.
CA3140231A 2019-05-16 2020-05-14 Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee Active CA3140231C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201910411311.X 2019-05-16
CN201910411311 2019-05-16
PCT/CN2019/100846 WO2020035040A1 (fr) 2018-08-17 2019-08-15 Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, et utilisation associée
CNPCT/CN2019/100846 2019-08-15
CN202010093736.3A CN111943943A (zh) 2019-05-16 2020-02-14 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
CN202010093736.3 2020-02-14
PCT/CN2020/090354 WO2020228789A1 (fr) 2019-05-16 2020-05-14 Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, forme cristalline et utilisation associée

Publications (2)

Publication Number Publication Date
CA3140231A1 CA3140231A1 (fr) 2020-11-19
CA3140231C true CA3140231C (fr) 2024-06-04

Family

ID=73336943

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140231A Active CA3140231C (fr) 2019-05-16 2020-05-14 Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee

Country Status (2)

Country Link
CN (1) CN111943943A (fr)
CA (1) CA3140231C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7272709B2 (ja) 2018-08-17 2023-05-12 シャンハイ リード ファーマテック カンパニー リミテッド ３－アリールオキシル－３－５員ヘテロアリール－プロピルアミン化合物およびその使用
WO2020228789A1 (fr) 2019-05-16 2020-11-19 上海璃道医药科技有限公司 Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, forme cristalline et utilisation associée
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
CN115703767A (zh) * 2021-08-12 2023-02-17 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0112122D0 (en) * 2001-05-18 2001-07-11 Lilly Co Eli Heteroaryloxy 3-substituted propanamines
CN107840845B (zh) * 2016-09-19 2024-07-02 上海璃道医药科技有限公司 胺类化合物的新用途
EP3339307A1 (fr) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Dérivés bicycliques contenant de l'azote destinés à traiter la douleur et des états liés à la douleur
WO2020035070A1 (fr) * 2018-08-17 2020-02-20 漳州片仔癀药业股份有限公司 Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
JP7272709B2 (ja) * 2018-08-17 2023-05-12 シャンハイ リード ファーマテック カンパニー リミテッド ３－アリールオキシル－３－５員ヘテロアリール－プロピルアミン化合物およびその使用

Also Published As

Publication number Publication date
CA3140231A1 (fr) 2020-11-19
CN111943943A (zh) 2020-11-17

Similar Documents

Publication Publication Date Title
CA3140231C (fr) Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee
JP7272709B2 (ja) ３－アリールオキシル－３－５員ヘテロアリール－プロピルアミン化合物およびその使用
AU2020276005B2 (en) 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof
CA3029857C (fr) Compose d'acetylene aromatique ou d'ethylene aromatique, produit intermediaire, procede de preparation, composition pharmaceutique et leur utilisation
EP3838900B1 (fr) Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées
EP3610874A1 (fr) Composition pharmaceutique contenant un agoniste du mor et un agoniste du kor, et ses utilisations
JPWO2002100819A1 (ja) Ｎ−アリールフェニルアセトアミド誘導体及びそれを含有する医薬組成物
JP7446591B2 (ja) ３－アリールオキシ－３－５員ヘテロアリール－プロピルアミン化合物の調製方法および結晶形
JP2021505573A (ja) ベータ−２選択的アドレナリン性受容体アゴニスト
JPWO2005079845A1 (ja) 片頭痛予防薬
CN120097888B (zh) 二氢吲哚芳酸醚类衍生物及其制备方法与用途
PL125527B1 (en) Process for preparing n-/1-methyl-2-pyrrolidylmethyl/-2,3-dimethoxy-5-methylsulfamylbenzamide
KR20250045262A (ko) 신규 페닐프로파노이드 유도체 화합물을 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 조성물
CN119118863A (zh) 9-菲酰胺类衍生物及其制备方法与用途
KR20210040228A (ko) 항히스타민 화합물, 이들의 약학 조성물 및 의약 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

EEER Examination request

Effective date: 20211112

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250505

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250505